BillionToOne, Inc. filings document the regulatory record for a public molecular diagnostics company commercializing QCT-based prenatal and oncology testing. Recent Form 8-K disclosures furnish operating results, financial guidance, Regulation FD presentation materials and executive compensation arrangements, including the company’s annual incentive plan and equity-based payment provisions.
Proxy materials describe annual meeting mechanics, stockholder voting matters, board governance and related governance disclosures. Together, the filings address the company’s clinical testing revenue categories, Class A common stock compensation framework, furnished earnings materials and governance matters relevant to its Nasdaq-listed operating-company status.
BillionToOne, Inc. (BLLN) lists David Tsao, identified as an officer and director, as proposing to sell 20,000 Class A shares on October 5, 2026, with an aggregate market value of $2,162,950.69. Fidelity Brokerage Services LLC is named as the broker, and NASDAQ as the exchange. The notice also lists a 20,000-share stock option exercise from the issuer for cash on October 5, 2026, and earlier sales by David Tsao and the DT 2021 Irrevocable Trust. The remarks identify Icontrust LLC as trustee and Tsao as an account stakeholder.
BillionToOne, Inc. (BLLN) lists a proposed sale by Officer John Roderick ten Bosch of 2,834 Class A shares, with an aggregate market value of $297,995.10 and an approximate sale date of October 5, 2026. Fidelity Brokerage Services LLC is named as the broker. The notice also lists six Class A sales by John R. Ten Bosch from July 13 through September 24, 2026.
BillionToOne, Inc. (BLLN) is named as issuer in a Form 144 notice listing a proposed sale of 1,750 Class A shares, with an aggregate market value of $184,012.50 and an approximate sale date of October 5, 2026. The shares are held in the Dt 2021 Irrevocable Trust account, with Icontrust LLC as trustee; David Tsao is an account stakeholder. The notice lists 42,644,388 Class A shares outstanding.
BillionToOne, Inc. (BLLN) Chairman and CEO Oguzhan Atay exercised 8,333 options at $2.80 per share on September 28, 2026, acquiring 8,333 Class A common shares and selling them at $120.64 per share under a Rule 10b5-1 plan adopted June 5, 2026. His spouse separately sold 2,666 shares at $120.64 per share that day under a plan adopted June 7, 2026; the spouse's reported indirect holdings after the sale were 154,502 shares. Atay's reported option position following the exercise was 493,629 options.
BillionToOne, Inc. (BLLN) Chief Technology Officer and director David Tsao exercised options to acquire 3,333 Class A common shares on September 24, 2026, at an exercise price of $2.80 per share, then sold 3,333 shares at $125 per share. The transactions were made under a Rule 10b5-1 trading plan adopted June 5, 2026. The derivative row reports 556,667 stock options following the exercise; the options were fully vested and exercisable.
BillionToOne, Inc. (BLLN) SVP of Laboratory Operations John Roderick ten Bosch sold 1,416 shares of Class A Common Stock at $120 per share on September 24, 2026. His reported direct holdings after the sale were 22,219 shares. The transaction was made under a Rule 10b5-1 trading plan adopted on June 2, 2026.
BillionToOne, Inc. (BLLN) is named as issuer in a Rule 144 notice listing 2,666 Class A shares for sale, with an aggregate market value of $321,626.24. The notice identifies Oguzhan Atay, an officer and director, as the person for whose account the securities are to be sold, while its remarks state that the current sale occurred in the account of his spouse, Ezgi N. Akcinar Atay. It also lists sales during the prior three months by Oguzhan Atay, Ezgi N. Akcinar Atay, and Atay 2021 Dynasty Trust; trust sales were made by Icontrust LLC, trustee.
BillionToOne, Inc. (BLLN) lists a proposed sale for Oguzhan Atay of 8,333 Class A shares on September 28, 2026, with an aggregate market value of $1,005,293.12. The shares are listed as acquired from the issuer through a stock option exercise for cash on September 28, 2026. The notice also lists Class A sales during the prior three months for Atay, his spouse Ezgi N. Akcinar Atay, and the Atay 2021 Dynasty Trust; Icontrust LLC acted as trustee for the trust sales, and Atay is an account stakeholder.
BillionToOne, Inc. is named as issuer in David Tsao’s notice to sell 3,333 Class A shares through Fidelity Brokerage Services LLC on Nasdaq on September 24, 2026, at an aggregate market value of $416,625.00. The shares were acquired from the issuer through a stock option exercise for cash.
The notice also lists prior Class A sales by David Tsao and the Dt 2021 Irrevocable Trust. Its remarks identify Icontrust LLC as trustee for the trust account and Tsao as a stakeholder.
BillionToOne, Inc. (BLLN) is named as issuer in officer John R. Ten Bosch’s Form 144 notice for the proposed sale of 1,416 Class A shares, with an aggregate market value of $169,920.00 and an approximate sale date of September 24, 2026. The notice lists 42,644,388 shares outstanding. It also reports six Class A sales by Ten Bosch during the prior three months, from June 29 through September 21, 2026.